A. Korfel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
A. Korfel has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
E. Thiel
13 shared publicationsL. Fischer
9 shared publications- K. Jahnke
Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Lübeck, Lübeck, Germany
7 shared publications P. Martus
7 shared publicationsM. Weller
5 shared publicationsE Thiel
4 shared publications
Latest Publications
- 1 November 2014
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 231 (S 01) , V12
Behandlung des primären intraokularen Lymphoms (PIOL): Ergebnisse des prospektiven Deutschen PIOL-Registers
Hintergrund: Die optimale Behandlung des primären intraokularen Non-Hodgkin-Lymphoms (PIOL) ist bisher ungeklärt. Wir berichten über die klinischen Charakteristika, Behandlung und Therapieergebnisse von neu diagnostizierten, immunkompetenten PIOL-Patienten, die im prospektiven Deutschen PIOL-Register (PIOL-R) eingeschlossen wurden. Methoden: Die patientenspezifischen Daten der PIOL-Patienten wurden prospektiv und nicht-interventionell durch einen standardisierten Erhebungsbogen in den kooperierenden ophthalmologischen und hämato-onkologischen Zentren erfasst. Ergebnisse: 28 Patienten (17 Frauen, Altersmedian 67 Jahre, medianer Karnofsky-Status 90%) konnten zwischen August 2008 und September 2014 eingeschlossen werden. Das mittlere Intervall zwischen Symptombeginn und PIOL-Diagnose war 5 (Spannweite 1–36) Monate. Bei allen Patienten lag ein diffuses großzelliges B-Zell-Lymphom vor. Die first-line-Behandlung bestand bei 22 Patienten aus systemischer Hochdosis-Methotrexat (MTX)- oder Ifosfamid-Therapie mit oder ohne Rituximab. Bei 4 Patienten wurde eine autologe Stammzelltransplantation (ASCT), eine intraokulare Chemotherapie mit Methotrexat (n = 1) und/oder Rituximab (n = 11) verwendet. Eine Strahlentherapie wurde bei 2 und eine isolierte Vitrektomie bei einem Patienten durchgeführt. Zwei Patienten erhielten prophylaktisch eine intrathekale MTX-Behandlung. Die PIOL-Remissionsrate betrug 100% mit kompletter Remission bei 19/23 auswertbaren Patienten, eine Teilremission lag bei 4 Patienten vor. Das mediane progressionsfreie Überleben der Patienten ohne vorangegangene ZNS-Beteiligung (n = 23) lag bei 21 (95% Konfidenzintervall 1,2 – 39,9) Monaten. Rezidive wurden im ZNS (n = 9), Auge (n = 3), Auge/ZNS (n = 3) und Auge/Meningen (n = 1) beobachtet und wurden mit systemischer Chemotherapie bei 12 (einschließlich Hochdosis-Chemotherapie mit ASCT bei 3), systemischer und intraokularer Chemotherapie bei einem sowie Radiotherapie des ZNS/der Neuroachse bei 2 Patienten behandelt. Schlussfolgerungen: Obwohl sich die diagnostischen Möglichkeiten hinsichtlich des PIOL in den letzten Jahren verbessert haben, wird weiterhin ein relativ langes Intervall von der Symptompräsentation bis zur Diagnose beobachtet. Bei den Behandlungsregimes ist tendenziell eine Verlagerung von der lokalen okularen Behandlung zur systemischen Therapie festzustellen. Dennoch bleiben die Rezidivraten sowie die Rate an Hirnbeteiligungen weiterhin hoch.
- 1 November 2014
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 231 (S 01) , V12
Behandlung des primären intraokularen Lymphoms (PIOL): Ergebnisse des prospektiven Deutschen PIOL-Registers
Hintergrund: Die optimale Behandlung des primären intraokularen Non-Hodgkin-Lymphoms (PIOL) ist bisher ungeklärt. Wir berichten über die klinischen Charakteristika, Behandlung und Therapieergebnisse von neu diagnostizierten, immunkompetenten PIOL-Patienten, die im prospektiven Deutschen PIOL-Register (PIOL-R) eingeschlossen wurden. Methoden: Die patientenspezifischen Daten der PIOL-Patienten wurden prospektiv und nicht-interventionell durch einen standardisierten Erhebungsbogen in den kooperierenden ophthalmologischen und hämato-onkologischen Zentren erfasst. Ergebnisse: 28 Patienten (17 Frauen, Altersmedian 67 Jahre, medianer Karnofsky-Status 90%) konnten zwischen August 2008 und September 2014 eingeschlossen werden. Das mittlere Intervall zwischen Symptombeginn und PIOL-Diagnose war 5 (Spannweite 1–36) Monate. Bei allen Patienten lag ein diffuses großzelliges B-Zell-Lymphom vor. Die first-line-Behandlung bestand bei 22 Patienten aus systemischer Hochdosis-Methotrexat (MTX)- oder Ifosfamid-Therapie mit oder ohne Rituximab. Bei 4 Patienten wurde eine autologe Stammzelltransplantation (ASCT), eine intraokulare Chemotherapie mit Methotrexat (n = 1) und/oder Rituximab (n = 11) verwendet. Eine Strahlentherapie wurde bei 2 und eine isolierte Vitrektomie bei einem Patienten durchgeführt. Zwei Patienten erhielten prophylaktisch eine intrathekale MTX-Behandlung. Die PIOL-Remissionsrate betrug 100% mit kompletter Remission bei 19/23 auswertbaren Patienten, eine Teilremission lag bei 4 Patienten vor. Das mediane progressionsfreie Überleben der Patienten ohne vorangegangene ZNS-Beteiligung (n = 23) lag bei 21 (95% Konfidenzintervall 1,2 – 39,9) Monaten. Rezidive wurden im ZNS (n = 9), Auge (n = 3), Auge/ZNS (n = 3) und Auge/Meningen (n = 1) beobachtet und wurden mit systemischer Chemotherapie bei 12 (einschließlich Hochdosis-Chemotherapie mit ASCT bei 3), systemischer und intraokularer Chemotherapie bei einem sowie Radiotherapie des ZNS/der Neuroachse bei 2 Patienten behandelt. Schlussfolgerungen: Obwohl sich die diagnostischen Möglichkeiten hinsichtlich des PIOL in den letzten Jahren verbessert haben, wird weiterhin ein relativ langes Intervall von der Symptompräsentation bis zur Diagnose beobachtet. Bei den Behandlungsregimes ist tendenziell eine Verlagerung von der lokalen okularen Behandlung zur systemischen Therapie festzustellen. Dennoch bleiben die Rezidivraten sowie die Rate an Hirnbeteiligungen weiterhin hoch.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 2026
Impact of meningeal dissemination (MD) on outcome in primary CNS lymphoma in the G-PCNSL-SG1 trial
2026 Background: The prognostic impact of MD in PCNSL is still debated. Within the framework of a multicenter randomized trial (G-PCNSL-SG1) we evaluated patients for outcome according to the presence of MD. Methods: Immunocompetent adult patients were initially treated with up to six cycles of high-dose methotrexate (HD-MTX; 4g/m2) based chemotherapy without intrathecal therapy. Those randomized to radiotherapy subsequently received whole-brain radiotherapy (WBRT) with 45 Gy, in 1.5 Gy fractions; those randomized to chemotherapy did not receive further therapy in case of complete remission or high-dose cytarabine when complete response was not achieved. MD was defined by the presence of lymphoma cells in the CSF detected by at least one of the following methods: cytomorphology, detection of clonal B cells by IgH-PCR or contrast enhancement of the leptomeninges on MRI. Results: All 526 patients fulfilling the eligibility criteria were entered into the analysis. MD at presentation was detected in 104 (19.8 %) patients: 95 by cytomorphology, 16 by PCR and 17 by MRI. Pretherapeutic characteristics including age, Karnofsky performance score, sex, serum lactate dehydrogenase, lymphoma localization, mode of biopsy, histology, CSF protein elevation (>45mg/dl) and ocular involvement did not significantly differ in patients with MD and other patients (all p>0.05). Only CSF pleocytosis (>5/µl) was significantly more frequent in patients with MD (37 vs. 14%, p<0.001). The type of chemotherapy (HD-MTX: 83 vs. 75%, HD-MTX and ifosfamide: 17 vs. 25%) applied and the frequency of WBRT (39 vs. 34%) were not significantly different in the group with and without MD. Median overall survival (OAS) in the MD group was 21.5 (95% CI 17.1-25.8) months as compared to 22.4 (17.3-27.5) months in other patients (p=0.8); median progression free survival (PFS) was 6.1 (1.6-10.5) and 7.0 (5.2-8.8) months, respectively (p=0.9). Median OAS and PFS were not significantly different in patients with elevated CSF protein or CSF pleocytosis compared to patients with normal CSF values. Conclusions: MD, elevated CSF protein and CSF pleocytosis had no impact on outcome in this trial.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 2026
Impact of meningeal dissemination (MD) on outcome in primary CNS lymphoma in the G-PCNSL-SG1 trial
2026 Background: The prognostic impact of MD in PCNSL is still debated. Within the framework of a multicenter randomized trial (G-PCNSL-SG1) we evaluated patients for outcome according to the presence of MD. Methods: Immunocompetent adult patients were initially treated with up to six cycles of high-dose methotrexate (HD-MTX; 4g/m2) based chemotherapy without intrathecal therapy. Those randomized to radiotherapy subsequently received whole-brain radiotherapy (WBRT) with 45 Gy, in 1.5 Gy fractions; those randomized to chemotherapy did not receive further therapy in case of complete remission or high-dose cytarabine when complete response was not achieved. MD was defined by the presence of lymphoma cells in the CSF detected by at least one of the following methods: cytomorphology, detection of clonal B cells by IgH-PCR or contrast enhancement of the leptomeninges on MRI. Results: All 526 patients fulfilling the eligibility criteria were entered into the analysis. MD at presentation was detected in 104 (19.8 %) patients: 95 by cytomorphology, 16 by PCR and 17 by MRI. Pretherapeutic characteristics including age, Karnofsky performance score, sex, serum lactate dehydrogenase, lymphoma localization, mode of biopsy, histology, CSF protein elevation (>45mg/dl) and ocular involvement did not significantly differ in patients with MD and other patients (all p>0.05). Only CSF pleocytosis (>5/µl) was significantly more frequent in patients with MD (37 vs. 14%, p<0.001). The type of chemotherapy (HD-MTX: 83 vs. 75%, HD-MTX and ifosfamide: 17 vs. 25%) applied and the frequency of WBRT (39 vs. 34%) were not significantly different in the group with and without MD. Median overall survival (OAS) in the MD group was 21.5 (95% CI 17.1-25.8) months as compared to 22.4 (17.3-27.5) months in other patients (p=0.8); median progression free survival (PFS) was 6.1 (1.6-10.5) and 7.0 (5.2-8.8) months, respectively (p=0.9). Median OAS and PFS were not significantly different in patients with elevated CSF protein or CSF pleocytosis compared to patients with normal CSF values. Conclusions: MD, elevated CSF protein and CSF pleocytosis had no impact on outcome in this trial.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 2004
Prognostic factors for response and survival in primary central nervous system lymphoma (PCNSL) from a randomized phase III trial (G-PCNSL-SG-1).
2004 Background: The purpose of this study was to establish prognostic factors in newly diagnosed primary central nervous system lymphoma (PCNSL) in immunocompetent patients. Methods: Four-hundred and eleven patients (median age 63 years, median Karnofsky performance status (KPS) 70%) enrolled in a German multicenter randomized phase III trial (G-PCNSL-SG-1) between May 2000 and May 2009 were analyzed using univariate and multivariate logistic regression analyses to identify prognostic factors for overall response (OR) and progression-free (PFS) and overall survival (OS). Patients were treated upfront with high-dose methotrexate (HDMTX) or HDMTX plus ifosfamide and were whole-brain irradiated thereafter if randomized to radiotherapy and treated with high-dose cytarabine (patients without complete remission) or just followed-up (patients with complete remission) if randomized to chemotherapy alone. Results: On multivariate analysis, female gender (p = 0.003), no corticosteroid medication at study entry (p = 0.003) and p ≥0.01) on multivariate analysis were: HDMTX plus ifosfamide vs. HDMTX monotherapy (for OR), body mass index ≤25 (for OS), <2 tumor lesions (for PFS and OS), and KPS ≥70% (for PFS). Conclusions: This is the first study that established prognostic factors for OR and survival in PCNSL derived from a multicenter, prospective, randomized phase III trial. The data, especially the strong association of age and KPS with OS, should be taken into consideration in the design of future studies in PCNSL.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 2004
Prognostic factors for response and survival in primary central nervous system lymphoma (PCNSL) from a randomized phase III trial (G-PCNSL-SG-1).
2004 Background: The purpose of this study was to establish prognostic factors in newly diagnosed primary central nervous system lymphoma (PCNSL) in immunocompetent patients. Methods: Four-hundred and eleven patients (median age 63 years, median Karnofsky performance status (KPS) 70%) enrolled in a German multicenter randomized phase III trial (G-PCNSL-SG-1) between May 2000 and May 2009 were analyzed using univariate and multivariate logistic regression analyses to identify prognostic factors for overall response (OR) and progression-free (PFS) and overall survival (OS). Patients were treated upfront with high-dose methotrexate (HDMTX) or HDMTX plus ifosfamide and were whole-brain irradiated thereafter if randomized to radiotherapy and treated with high-dose cytarabine (patients without complete remission) or just followed-up (patients with complete remission) if randomized to chemotherapy alone. Results: On multivariate analysis, female gender (p = 0.003), no corticosteroid medication at study entry (p = 0.003) and p ≥0.01) on multivariate analysis were: HDMTX plus ifosfamide vs. HDMTX monotherapy (for OR), body mass index ≤25 (for OS), <2 tumor lesions (for PFS and OS), and KPS ≥70% (for PFS). Conclusions: This is the first study that established prognostic factors for OR and survival in PCNSL derived from a multicenter, prospective, randomized phase III trial. The data, especially the strong association of age and KPS with OS, should be taken into consideration in the design of future studies in PCNSL.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15_suppl) , 8008
Should whole-brain radiotherapy be considered standard of care in newly diagnosed primary central nervous system lymphoma? The G-PCNSL-SG1 randomized phase IV trial.
8008 Background: High-dose methotrexate (HDMTX) is considered the standard of care for patients with newly diagnosed primary central nervous system lymphoma (PCNSL). The role of whole-brain radiotherapy (WBRT) has remained controversial. Delayed neurotoxicity limits its acceptance as a standard of care. Methods: Immunocompetent patients with newly diagnosed PCNSL were randomized to chemotherapy followed by WBRT (arms A1, B1) or chemotherapy alone (A2, B2). After randomization, all patients were to receive 6 cycles HDMTX (4 g/m2, D1, biweekly) from 1999-2007 and HDMTX plus ifosfamide (1.5 g/m2, D3-D5, biweekly) thereafter. Patients achieving a complete response (CR) received either consolidating WBRT with 45 Gy in 1.5 Gy fractions (arm A1) or no further treatment (A2). Patients without CR received salvage WBRT (B1) or salvage chemotherapy using HD-cytarabine (B2) (4 × 3 g/m2/ 48 h, × 3 weeks). The goal of the trial was to demonstrate that the omission of WBRT from first-line treatment does not compromise overall survival (OS) as the primary endpoint. Results: 551 patients (median age 63 years) entered the study, and 537 received at least one course HDMTX-based chemotherapy. Of those, 66 died on HDMTX, 60 dropped out, 411 entered the post-HDMTX phase, and 318 were treated per protocol (PP population). For this PP population, median OS was 32.4 months in the chemotherapy+WBRT arm (A1+B1, n=154) and 37.1 months in the chemotherapy alone arm (A2+B2, n=164) (p=0.80). The median progression-free survival (PFS) was 18.3 and 12 months (p=0.13), respectively. Conclusions: This largest PCNSL trial ever performed world-wide showed no difference in OS when WBRT was omitted from HDMTX-based chemotherapy in patients with newly diagnosed PCNSL. No significant financial relationships to disclose.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15_suppl) , 8008
Should whole-brain radiotherapy be considered standard of care in newly diagnosed primary central nervous system lymphoma? The G-PCNSL-SG1 randomized phase IV trial.
8008 Background: High-dose methotrexate (HDMTX) is considered the standard of care for patients with newly diagnosed primary central nervous system lymphoma (PCNSL). The role of whole-brain radiotherapy (WBRT) has remained controversial. Delayed neurotoxicity limits its acceptance as a standard of care. Methods: Immunocompetent patients with newly diagnosed PCNSL were randomized to chemotherapy followed by WBRT (arms A1, B1) or chemotherapy alone (A2, B2). After randomization, all patients were to receive 6 cycles HDMTX (4 g/m2, D1, biweekly) from 1999-2007 and HDMTX plus ifosfamide (1.5 g/m2, D3-D5, biweekly) thereafter. Patients achieving a complete response (CR) received either consolidating WBRT with 45 Gy in 1.5 Gy fractions (arm A1) or no further treatment (A2). Patients without CR received salvage WBRT (B1) or salvage chemotherapy using HD-cytarabine (B2) (4 × 3 g/m2/ 48 h, × 3 weeks). The goal of the trial was to demonstrate that the omission of WBRT from first-line treatment does not compromise overall survival (OS) as the primary endpoint. Results: 551 patients (median age 63 years) entered the study, and 537 received at least one course HDMTX-based chemotherapy. Of those, 66 died on HDMTX, 60 dropped out, 411 entered the post-HDMTX phase, and 318 were treated per protocol (PP population). For this PP population, median OS was 32.4 months in the chemotherapy+WBRT arm (A1+B1, n=154) and 37.1 months in the chemotherapy alone arm (A2+B2, n=164) (p=0.80). The median progression-free survival (PFS) was 18.3 and 12 months (p=0.13), respectively. Conclusions: This largest PCNSL trial ever performed world-wide showed no difference in OS when WBRT was omitted from HDMTX-based chemotherapy in patients with newly diagnosed PCNSL. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 2030
Ifosfamide or trofosfamide in patients with intraocular lymphoma: Final report
2030 Background: This abstract reports the long-term results of intraocular lymphoma (IOL) patients treated with ifosfamide (IFO) or trofosfamide (TRO). Methods: We previously reported the efficacy of intravenous IFO and oral TRO in a single center prospective study on 10 patients with IOL. IFO was given at a dose of 1,500 (≥65 years) or 2,000 (<65 years) mg/m²/day on days 1–3 and TRO at a dose of 150 and 400 mg/day (continuous or intermittent administration). Remission rate, progression-free survival (PFS), overall survival (OS) and long-term toxicity were evaluated in this follow-up analysis. Results: All patients responded to first treatment with IFO or TRO, including nine complete remissions and one partial remission. Median PFS from the first treatment with IFO or TRO was 18 (range, 7–36) months. Seven patients relapsed: five in the eye and two in the brain. Four patients were retreated with IFO or TRO on relapse, three of whom responded. Median OS was 32 (range, 7–37+) months. Acute toxicity was mainly hematologic. No long-term toxicity was observed in patients treated with IFO or TRO alone. Conclusions: Response rates to IFO and TRO are high with tolerable toxicity. Combination treatment of IFO/TRO with other cytostatics is warranted to improve long-term disease control. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 2030
Ifosfamide or trofosfamide in patients with intraocular lymphoma: Final report
2030 Background: This abstract reports the long-term results of intraocular lymphoma (IOL) patients treated with ifosfamide (IFO) or trofosfamide (TRO). Methods: We previously reported the efficacy of intravenous IFO and oral TRO in a single center prospective study on 10 patients with IOL. IFO was given at a dose of 1,500 (≥65 years) or 2,000 (<65 years) mg/m²/day on days 1–3 and TRO at a dose of 150 and 400 mg/day (continuous or intermittent administration). Remission rate, progression-free survival (PFS), overall survival (OS) and long-term toxicity were evaluated in this follow-up analysis. Results: All patients responded to first treatment with IFO or TRO, including nine complete remissions and one partial remission. Median PFS from the first treatment with IFO or TRO was 18 (range, 7–36) months. Seven patients relapsed: five in the eye and two in the brain. Four patients were retreated with IFO or TRO on relapse, three of whom responded. Median OS was 32 (range, 7–37+) months. Acute toxicity was mainly hematologic. No long-term toxicity was observed in patients treated with IFO or TRO alone. Conclusions: Response rates to IFO and TRO are high with tolerable toxicity. Combination treatment of IFO/TRO with other cytostatics is warranted to improve long-term disease control. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 2029
Prospective evaluation of meningeal involvement in primary CNS lymphoma (PCNSL)
2029 Background: The prognostic impact of meningeal dissemination (MD) in PCNSL is still debated, and the reported incidence varies. Sensitive methods like polymerase chain reaction (PCR) might enhance the diagnostic accuracy to detect clonal cells in the cerebrospinal fluid (CSF). We prospectively evaluated the diagnostic value of PCR in comparison with CSF cytomorphology and cerebral magnetic resonance imaging (MRI) for diagnosing MD in PCNSL. Methods: A total of 282 patients from a multicenter therapy trial for PCNSL were evaluated for the presence of MD: 217 with cranial MRI, 205 with CSF cytomorphology and 171 with PCR of the rearranged immunoglobulin heavy-chain CDRIII region genes in CSF. A CSF protein ≥45mg/dl and a CSF cell count > 5/μl were denoted as abnormal. Results: MD was found in 33 of 205 patients (16%) by cytomorphologic examination, in 19 of 171 (11%) patients evaluated by PCR and in eight of 216 patients (4%) by MRI. Considering all methods, the incidence of MD was 17.4% (49 of 282 patients). PCR was monoclonal in six of 19 samples (32%) with positive, in one of 13 samples (7.7%) with suspicious, and in ten of 105 (9.5%) samples with negative cytology. In 11 samples with positive and 12 with suspicious cytology PCR was polyclonal. Of the eight MRI positive patients, CSF cytology was positive in five (two patients not evaluated), and a monoclonal PCR product was found in two (six patients not evaluated). MD was more probable in cases with CSF pleocytosis with an odds ratio of 2.48 (95% CI: 1.15 - 5.34, p=0.018), whereas CSF protein had no predictive value for MD detection. Pleocytosis correlated significantly with a positive cytology (23% vs. 5%, p=0.001) but not with MD detection by PCR. Conclusions: A low incidence of MD in PCNSL was found in this large prospective study, despite the use of PCR. The diagnostic accuracy was enhanced by PCR, however, discordant PCR and cytologic results were frequent. CSF pleocytosis had predictive value for MD detection. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 2029
Prospective evaluation of meningeal involvement in primary CNS lymphoma (PCNSL)
2029 Background: The prognostic impact of meningeal dissemination (MD) in PCNSL is still debated, and the reported incidence varies. Sensitive methods like polymerase chain reaction (PCR) might enhance the diagnostic accuracy to detect clonal cells in the cerebrospinal fluid (CSF). We prospectively evaluated the diagnostic value of PCR in comparison with CSF cytomorphology and cerebral magnetic resonance imaging (MRI) for diagnosing MD in PCNSL. Methods: A total of 282 patients from a multicenter therapy trial for PCNSL were evaluated for the presence of MD: 217 with cranial MRI, 205 with CSF cytomorphology and 171 with PCR of the rearranged immunoglobulin heavy-chain CDRIII region genes in CSF. A CSF protein ≥45mg/dl and a CSF cell count > 5/μl were denoted as abnormal. Results: MD was found in 33 of 205 patients (16%) by cytomorphologic examination, in 19 of 171 (11%) patients evaluated by PCR and in eight of 216 patients (4%) by MRI. Considering all methods, the incidence of MD was 17.4% (49 of 282 patients). PCR was monoclonal in six of 19 samples (32%) with positive, in one of 13 samples (7.7%) with suspicious, and in ten of 105 (9.5%) samples with negative cytology. In 11 samples with positive and 12 with suspicious cytology PCR was polyclonal. Of the eight MRI positive patients, CSF cytology was positive in five (two patients not evaluated), and a monoclonal PCR product was found in two (six patients not evaluated). MD was more probable in cases with CSF pleocytosis with an odds ratio of 2.48 (95% CI: 1.15 - 5.34, p=0.018), whereas CSF protein had no predictive value for MD detection. Pleocytosis correlated significantly with a positive cytology (23% vs. 5%, p=0.001) but not with MD detection by PCR. Conclusions: A low incidence of MD in PCNSL was found in this large prospective study, despite the use of PCR. The diagnostic accuracy was enhanced by PCR, however, discordant PCR and cytologic results were frequent. CSF pleocytosis had predictive value for MD detection. No significant financial relationships to disclose.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 6718
Central nervous system involvement in non-Hodgkin’s lymphoma: A single-center analysis of prognostic factors for survival
6718 Background: The prognosis of patients with non-Hodgkin’s lymphoma (NHL) and central nervous system (CNS) involvement is generally regarded as poor. Very little is known about prognostic factors in these patients. The aim of this retrospective single-center study was to analyze the clinical characteristics and outcome of NHL patients with CNS involvement and identify prognostic factors for survival. Methods: We searched our hospital records for NHL patients with CNS involvement diagnosed from 1982 to 2003, and 43 were identified. Prognostic factors for survival were assessed by univariate and multivariate analysis. Results: The median age at CNS manifestation was 61 (range, 22–87); the median Karnofsky performance status was 55 (range 10–90). Thirty-five patients had CNS relapse and 8 patients CNS involvement at first presentation. Isolated CNS disease was found in 6 patients and concomitant systemic disease in 36. Initial management included systemic chemotherapy (n=25), chemo-/radiotherapy (n=16), dexamethasone (n=1), and no treatment (n=1). Chemotherapy consisted of CNS-penetrating drugs (high-dose methotrexate or ifosfamide) in 24 patients. Intrathecal chemotherapy was given to 34 patients. Twenty-six patients showed a CNS response. The median survival from the time of CNS manifestation and the median overall survival (OAS) were 5.5 (0–82.5+) and 37 (0–181) months, respectively. Lactate dehydrogenase (LDH) at CNS manifestation (p = .051) and CNS response to therapy were identified as independent prognostic factors for survival on multivariate analysis (p = <.001), whereas age at initial diagnosis, initial CNS involvement, initial LDH, and treatment with CNS-penetrating chemotherapy for CNS involvement were only significant on univariate analysis. All but one of 9 patients who are still alive received substances able to sufficiently penetrate the blood-brain barrier. All survivors were disease-free at the last follow-up. Conclusions: Long-term survival can be achieved in patients with NHL and CNS involvement. LDH at CNS manifestation and CNS response to therapy were significantly associated with survival. No significant financial relationships to disclose.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 6718
Central nervous system involvement in non-Hodgkin’s lymphoma: A single-center analysis of prognostic factors for survival
6718 Background: The prognosis of patients with non-Hodgkin’s lymphoma (NHL) and central nervous system (CNS) involvement is generally regarded as poor. Very little is known about prognostic factors in these patients. The aim of this retrospective single-center study was to analyze the clinical characteristics and outcome of NHL patients with CNS involvement and identify prognostic factors for survival. Methods: We searched our hospital records for NHL patients with CNS involvement diagnosed from 1982 to 2003, and 43 were identified. Prognostic factors for survival were assessed by univariate and multivariate analysis. Results: The median age at CNS manifestation was 61 (range, 22–87); the median Karnofsky performance status was 55 (range 10–90). Thirty-five patients had CNS relapse and 8 patients CNS involvement at first presentation. Isolated CNS disease was found in 6 patients and concomitant systemic disease in 36. Initial management included systemic chemotherapy (n=25), chemo-/radiotherapy (n=16), dexamethasone (n=1), and no treatment (n=1). Chemotherapy consisted of CNS-penetrating drugs (high-dose methotrexate or ifosfamide) in 24 patients. Intrathecal chemotherapy was given to 34 patients. Twenty-six patients showed a CNS response. The median survival from the time of CNS manifestation and the median overall survival (OAS) were 5.5 (0–82.5+) and 37 (0–181) months, respectively. Lactate dehydrogenase (LDH) at CNS manifestation (p = .051) and CNS response to therapy were identified as independent prognostic factors for survival on multivariate analysis (p = <.001), whereas age at initial diagnosis, initial CNS involvement, initial LDH, and treatment with CNS-penetrating chemotherapy for CNS involvement were only significant on univariate analysis. All but one of 9 patients who are still alive received substances able to sufficiently penetrate the blood-brain barrier. All survivors were disease-free at the last follow-up. Conclusions: Long-term survival can be achieved in patients with NHL and CNS involvement. LDH at CNS manifestation and CNS response to therapy were significantly associated with survival. No significant financial relationships to disclose.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 2530
Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer
2530 Background: Ertumaxomab is an intact bispecific monoclonal antibody targeting HER2 and CD3. The heavy chain is composed of murine IgG2a and rat IgG2b subclasses with strong binding to activatory Fcγ-RI/III-receptors of accessory immune cells. The formation of a tri-cell complex between tumor cell, T-cell and accessory cell results in tumor cell killing by various immunological mechanisms. Methods: Seventeen patients with metastatic breast cancer were enrolled into a multi-center phase I dose-escalating trial. Three ascending doses (10–200μg) were administered intravenously on day 1, 7±1 and 13±1. Patients were followed up for 69 days. Safety and tolerability were primary Objectives: Secondary variables were anti-tumor activity and measurement of different immunological parameters (cytokines, hematological markers). Results: Sixteen out of 17 enrolled patients with a median age of 60,5 years and a HER2-expression score of 1+ (25%), 2+ (12.5%), and 3+ (62,5%) have completed the study up to date. 100μg was identified as maximal tolerable single dose. Most adverse events were mild and transient including fever (75%), chills (50%), nausea (44%), vomiting (25%), pain (38%). Grade 3/4 (CTC) were lymphocytopenia (69%) and elevation of liver enzymes (38%). One patient (200μg dose) developed severe hypotension and respiratory distress syndrome, one patient (150μg dose) developed a systemic inflammatory response syndrome and acute renal failure. All adverse events were fully reversible. Aggravation of congestive heart-failure was seen in a patient (200μg dose) with pre-existing ventricular dysfunction. Antitumor response was seen in 4 out of 15 evaluable patients (1CR, 2 PR, 1 SD) at dose levels of ≥100μg. Measurement of cytokines (IL-6, IL-2, TNF-α, IFN-γ) suggests a strong Th1-associated immune response. Induction of human-anti-mouse/rat-antibodies (HAMA/HARA) was detected in 3 patients (19%) only. Conclusions: Treatment with triple infusions of ertumaxomab yields a strong immunological response. Doses up to 100 μg can be safely infused with close monitoring of patients. Tumor response in some patients is encouraging suggesting anti-tumor efficacy. No significant financial relationships to disclose.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 2530
Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer
2530 Background: Ertumaxomab is an intact bispecific monoclonal antibody targeting HER2 and CD3. The heavy chain is composed of murine IgG2a and rat IgG2b subclasses with strong binding to activatory Fcγ-RI/III-receptors of accessory immune cells. The formation of a tri-cell complex between tumor cell, T-cell and accessory cell results in tumor cell killing by various immunological mechanisms. Methods: Seventeen patients with metastatic breast cancer were enrolled into a multi-center phase I dose-escalating trial. Three ascending doses (10–200μg) were administered intravenously on day 1, 7±1 and 13±1. Patients were followed up for 69 days. Safety and tolerability were primary Objectives: Secondary variables were anti-tumor activity and measurement of different immunological parameters (cytokines, hematological markers). Results: Sixteen out of 17 enrolled patients with a median age of 60,5 years and a HER2-expression score of 1+ (25%), 2+ (12.5%), and 3+ (62,5%) have completed the study up to date. 100μg was identified as maximal tolerable single dose. Most adverse events were mild and transient including fever (75%), chills (50%), nausea (44%), vomiting (25%), pain (38%). Grade 3/4 (CTC) were lymphocytopenia (69%) and elevation of liver enzymes (38%). One patient (200μg dose) developed severe hypotension and respiratory distress syndrome, one patient (150μg dose) developed a systemic inflammatory response syndrome and acute renal failure. All adverse events were fully reversible. Aggravation of congestive heart-failure was seen in a patient (200μg dose) with pre-existing ventricular dysfunction. Antitumor response was seen in 4 out of 15 evaluable patients (1CR, 2 PR, 1 SD) at dose levels of ≥100μg. Measurement of cytokines (IL-6, IL-2, TNF-α, IFN-γ) suggests a strong Th1-associated immune response. Induction of human-anti-mouse/rat-antibodies (HAMA/HARA) was detected in 3 patients (19%) only. Conclusions: Treatment with triple infusions of ertumaxomab yields a strong immunological response. Doses up to 100 μg can be safely infused with close monitoring of patients. Tumor response in some patients is encouraging suggesting anti-tumor efficacy. No significant financial relationships to disclose.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 8041
Comparison of high-dose methotrexate (HDMTX) toxicity in elderly and younger patients (pts) with primary central nervous system lymphoma (PCNSL)
8041 Background: A reduced dose of HDMTX is often given to elderly pts because of the risk of toxicity. This may result in loss of treatment efficacy and further prognosis impairment in this poor prognosis population. Methods: HDMTX toxicity was prospectively evaluated in an ongoing randomized multicenter phase IV study in PCNSL pts. In 154 pts, an analysis of toxicity according to the pts' age was performed. Median age was 61 years (yrs). Sixty-five pts were ≤ 60 yrs and had a median Karnofsky performance score (KPS) of 80, 89 pts were > 60 yrs and had a median KPS of 70. HDMTX (4 g/m2 per course) was administered as a 4-hour intravenous (IV) infusion on day 1 every 2 weeks for a maximum of 6 courses and was accompanied by IV hydration, urinary alkalinization, and leucovorin rescue at a dose of 30 mg IV every 6 hours after 24 hours of HDMTX infusion. HDMTX dose reduction was performed according to creatinine clearance values evaluated before each treatment course: the percentage of dose reduction equaled the percentage of creatinine clearance value below 100 ml/min. Results: Toxicity was generally mild to moderate. No statistically significant differences in frequency and severity of toxicity between pts ≤ 60 and > 60 yrs were noted (table). No therapy-related deaths occurred. Dose reduction due to decrease in creatinine clearance was much more frequent in pts > 60 yrs than in those ≤ 60 yrs (43.9 % versus 17.5 %, p = 0.001). Conclusions: HDMTX is safe regardless of age when dose reduction is performed according to creatinine clearance. Dose reduction solely according to age does not appear to be justified. No significant financial relationships to disclose.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 8041
Comparison of high-dose methotrexate (HDMTX) toxicity in elderly and younger patients (pts) with primary central nervous system lymphoma (PCNSL)
8041 Background: A reduced dose of HDMTX is often given to elderly pts because of the risk of toxicity. This may result in loss of treatment efficacy and further prognosis impairment in this poor prognosis population. Methods: HDMTX toxicity was prospectively evaluated in an ongoing randomized multicenter phase IV study in PCNSL pts. In 154 pts, an analysis of toxicity according to the pts' age was performed. Median age was 61 years (yrs). Sixty-five pts were ≤ 60 yrs and had a median Karnofsky performance score (KPS) of 80, 89 pts were > 60 yrs and had a median KPS of 70. HDMTX (4 g/m2 per course) was administered as a 4-hour intravenous (IV) infusion on day 1 every 2 weeks for a maximum of 6 courses and was accompanied by IV hydration, urinary alkalinization, and leucovorin rescue at a dose of 30 mg IV every 6 hours after 24 hours of HDMTX infusion. HDMTX dose reduction was performed according to creatinine clearance values evaluated before each treatment course: the percentage of dose reduction equaled the percentage of creatinine clearance value below 100 ml/min. Results: Toxicity was generally mild to moderate. No statistically significant differences in frequency and severity of toxicity between pts ≤ 60 and > 60 yrs were noted (table). No therapy-related deaths occurred. Dose reduction due to decrease in creatinine clearance was much more frequent in pts > 60 yrs than in those ≤ 60 yrs (43.9 % versus 17.5 %, p = 0.001). Conclusions: HDMTX is safe regardless of age when dose reduction is performed according to creatinine clearance. Dose reduction solely according to age does not appear to be justified. No significant financial relationships to disclose.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 8067
Rescue with recombinant Carboxypeptidase G2 (CPG2) in high-dose methotrexate (HD-MTX) induced renal failure: Results in 42 patients from a German emergency protocol
8067 Background: Accumulation of MTX in patients (pts.) with renal failure after HD-MTX is a rare, but life-threatening complication. Recombinant CPG2 cleaves MTX into the less toxic metabolite 2,4-diamino-N-pteroic acid (DAMPA) and glutamate. We have conducted an emergency use protocol using CPG2 in pts. with delayed MTX-elimination/renal failure after HD-MTX. Methods: Pts. with MTX serum levels of >5μmol/l at 42h, >1μmol/l at 42h* or >0.4μmol/l at 48h* (* + renal insufficiency: creatinine >1.5 upper limit of normal) after start of HD-MTX (>1g/m2 MTX) were eligible. Pts. with renal insufficiency were also eligible at <42h. Concentrations of MTX and metabolites were measured by high-performance-liquid-chromatography (HPLC) in acidified serum samples. Results: 42 pts. (age: 10–78 years) with lymphoma (29), acute lymphoblastic leukemia (12) or germ cell tumor (1) were enroled. MTX serum levels at registration ranged from 1.01 - 1187.42μmol/l (median: 9.8). CPG2 was given at dosages ranging from 10–58units/kg i.v. at median 55h (range: 27–176h) after start of HD-MTX. Except for skin reaction grade III and fever grade II in one pt. each, CPG2 was well tolerated. Serial serum samples were available for HPLC analysis in 24 pts.. MTX serum levels rapidly declined from a median of 5.11μmol/l (range: 0.35–165.86) to 1μmol/l or less within 7–50 minutes after CPG2 administration. Serum creatinine levels remained normal in 2 pts. and returned to normal values in 21 pts. after a median of 17 days (range: 4–127). The remaining 19 pts. had median peak serum creatinine levels of 283μmol/l which subsequently declined to a median of 150μmol/l by days 1–58 after CPG2. Conclusions: CPG2 is a safe and effective antidote in HD-MTX treated pts. with delayed MTX-clearance/renal failure. Further studies are needed to evaluate the efficacy of CPG2 with respect to clinical endpoints, as well as the role of this novel drug as a standard rescue agent.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 8067
Rescue with recombinant Carboxypeptidase G2 (CPG2) in high-dose methotrexate (HD-MTX) induced renal failure: Results in 42 patients from a German emergency protocol
8067 Background: Accumulation of MTX in patients (pts.) with renal failure after HD-MTX is a rare, but life-threatening complication. Recombinant CPG2 cleaves MTX into the less toxic metabolite 2,4-diamino-N-pteroic acid (DAMPA) and glutamate. We have conducted an emergency use protocol using CPG2 in pts. with delayed MTX-elimination/renal failure after HD-MTX. Methods: Pts. with MTX serum levels of >5μmol/l at 42h, >1μmol/l at 42h* or >0.4μmol/l at 48h* (* + renal insufficiency: creatinine >1.5 upper limit of normal) after start of HD-MTX (>1g/m2 MTX) were eligible. Pts. with renal insufficiency were also eligible at <42h. Concentrations of MTX and metabolites were measured by high-performance-liquid-chromatography (HPLC) in acidified serum samples. Results: 42 pts. (age: 10–78 years) with lymphoma (29), acute lymphoblastic leukemia (12) or germ cell tumor (1) were enroled. MTX serum levels at registration ranged from 1.01 - 1187.42μmol/l (median: 9.8). CPG2 was given at dosages ranging from 10–58units/kg i.v. at median 55h (range: 27–176h) after start of HD-MTX. Except for skin reaction grade III and fever grade II in one pt. each, CPG2 was well tolerated. Serial serum samples were available for HPLC analysis in 24 pts.. MTX serum levels rapidly declined from a median of 5.11μmol/l (range: 0.35–165.86) to 1μmol/l or less within 7–50 minutes after CPG2 administration. Serum creatinine levels remained normal in 2 pts. and returned to normal values in 21 pts. after a median of 17 days (range: 4–127). The remaining 19 pts. had median peak serum creatinine levels of 283μmol/l which subsequently declined to a median of 150μmol/l by days 1–58 after CPG2. Conclusions: CPG2 is a safe and effective antidote in HD-MTX treated pts. with delayed MTX-clearance/renal failure. Further studies are needed to evaluate the efficacy of CPG2 with respect to clinical endpoints, as well as the role of this novel drug as a standard rescue agent.